GENFIT (GNFT): רווח נקי למניה ב-12 החודשים האחרונים

The commercialization of PBC therapy and progress in treating steatohepatitis are driving growth for Genfit S.A. (GNFT). The 12-month net income per share snapshot on GURU.Markets confirms this trend, where the -0.91 level indicates the parameter's status. This paves the way for massive revenue scalability from a single molecule, while partnerships with industry behemoths successfully diversify the drug portfolio risks.
פילוחים אנליטיים של חברת Genfit S.A.

The rolling net income per share trend reflects the actual efficiency of Genfit S.A. (GNFT), demonstrating the business's ability to generate profit per share over a one-year period. This indicator is calculated by dividing the total net income over 12 months by the number of shares, allowing investors to assess capital stability amid geopolitical risks and logistical disruptions during global clinical trials.